← Back to headlines
HSBC Downgrades AstraZeneca Following Key Trial Failure
HSBC has downgraded AstraZeneca after the pharmaceutical company reported the failure of a key clinical trial, impacting its stock outlook.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Fed Chair Warsh Warns Persistent Inflation Requires Continued Policy Action
13m ago
Fed Chair Warsh Signals Potential Rate Hikes Amid Persistent Inflation at Jackson Hole
19m ago
Fed Official Warsh Warns US Inflation Remains Concerning, Pledges 2% Target
40m ago
Walmart Reaches Settlement With US Government Over Opioid Lawsuit
41m ago